Schmidt, Nina <br/><br/>
Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.  [electronic resource] 

 -  Atherosclerosis  10 2018 
 - 314-322 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-1484 
<br/><br/><label>Standard No.: </label>10.1016/j.atherosclerosis.2018.08.050  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anticholesteremic Agents--therapeutic use<br/>Biomarkers--blood<br/>Cardiovascular Diseases--epidemiology<br/>Cholesterol, LDL--blood<br/>Down-Regulation<br/>Drug Therapy, Combination<br/>Female<br/>Genetic Predisposition to Disease<br/>Germany--epidemiology<br/>Heredity<br/>Humans<br/>Hyperlipoproteinemia Type II--blood<br/>Male<br/>Middle Aged<br/>PCSK9 Inhibitors<br/>Pedigree<br/>Phenotype<br/>Proprotein Convertase 9--metabolism<br/>Risk Assessment<br/>Risk Factors<br/>Serine Endopeptidases--therapeutic use<br/>Time Factors<br/>Treatment Outcome